SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

FRASSOLDATI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.762
AS - Asia 4.844
EU - Europa 4.295
SA - Sud America 808
AF - Africa 133
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 3
Totale 18.861
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.573
FI - Finlandia 2.058
SG - Singapore 1.964
CN - Cina 1.068
BR - Brasile 656
VN - Vietnam 541
IT - Italia 500
DE - Germania 425
HK - Hong Kong 412
GB - Regno Unito 247
TR - Turchia 207
PL - Polonia 199
UA - Ucraina 170
FR - Francia 149
SE - Svezia 142
IN - India 125
RU - Federazione Russa 120
JP - Giappone 110
ID - Indonesia 101
MX - Messico 100
CA - Canada 64
BD - Bangladesh 55
NL - Olanda 54
AR - Argentina 53
ZA - Sudafrica 49
IQ - Iraq 42
TW - Taiwan 42
BE - Belgio 39
AT - Austria 35
ES - Italia 35
PK - Pakistan 24
EC - Ecuador 21
CL - Cile 19
LT - Lituania 18
CO - Colombia 17
SA - Arabia Saudita 17
UZ - Uzbekistan 17
MA - Marocco 16
AU - Australia 15
CZ - Repubblica Ceca 15
EG - Egitto 14
MY - Malesia 14
IE - Irlanda 13
VE - Venezuela 13
PH - Filippine 12
PY - Paraguay 12
PE - Perù 11
ET - Etiopia 10
TN - Tunisia 10
AL - Albania 9
DZ - Algeria 9
KE - Kenya 9
KR - Corea 9
OM - Oman 9
AE - Emirati Arabi Uniti 8
CH - Svizzera 8
PT - Portogallo 8
CR - Costa Rica 7
DK - Danimarca 7
JO - Giordania 7
IR - Iran 6
KZ - Kazakistan 6
LV - Lettonia 6
RO - Romania 6
HU - Ungheria 5
IL - Israele 5
PS - Palestinian Territory 5
TH - Thailandia 5
CI - Costa d'Avorio 4
GR - Grecia 4
KG - Kirghizistan 4
LB - Libano 4
NP - Nepal 4
PA - Panama 4
UY - Uruguay 4
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
KW - Kuwait 3
MD - Moldavia 3
NG - Nigeria 3
NO - Norvegia 3
QA - Qatar 3
RS - Serbia 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
BH - Bahrain 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
JM - Giamaica 2
MU - Mauritius 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
AM - Armenia 1
AO - Angola 1
Totale 18.844
Salva come PNG Salva come JPEG
Città #
Helsinki 2.015
Singapore 1.214
Ashburn 1.145
Fairfield 868
Woodbridge 751
Houston 468
San Jose 424
Chandler 416
Santa Clara 409
Hong Kong 401
Seattle 357
Beijing 353
Wilmington 330
Ann Arbor 321
Cambridge 304
Jacksonville 255
Warsaw 196
Munich 187
Ho Chi Minh City 169
Izmir 160
Los Angeles 137
New York 127
Hanoi 123
Dallas 121
Princeton 104
Tokyo 99
Lauterbourg 98
Nanjing 97
Council Bluffs 94
Ferrara 88
Jakarta 84
Shanghai 62
São Paulo 61
Milan 58
Mexico City 56
London 54
San Diego 53
Boardman 52
Chicago 52
The Dalles 44
Brussels 39
Orem 39
Nanchang 37
Falls Church 35
Dearborn 32
Hebei 32
Atlanta 31
Bologna 29
Chennai 28
Columbus 27
Tianjin 27
Nuremberg 26
Dong Ket 25
Johannesburg 25
Shenyang 25
Brooklyn 24
Haiphong 24
Montreal 24
Stockholm 24
Poplar 23
Redwood City 23
Turku 23
Changsha 22
Des Moines 22
Guangzhou 21
Boston 20
Da Nang 20
Buffalo 19
Rio de Janeiro 19
Norwalk 18
Phoenix 18
Denver 17
Mumbai 17
Tashkent 17
Biên Hòa 16
Bremen 16
Frankfurt am Main 16
Baghdad 15
Belo Horizonte 15
Moscow 15
Vienna 15
Amsterdam 14
Shenzhen 14
Toronto 14
Charlotte 13
Falkenstein 13
Jiaxing 13
Manchester 13
Hefei 12
San Francisco 12
Verona 12
Kunming 11
Mountain View 11
Querétaro 11
Rome 11
Salt Lake City 11
Salvador 11
Addison 10
Dublin 10
Hải Dương 10
Totale 13.593
Salva come PNG Salva come JPEG
Nome #
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 2.075
Absolute quantification of cell-free microRNAs in cancer patients 328
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma 296
Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR 293
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy 290
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 262
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study 260
miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model 260
Gastrointestinal stromal tumors and other malignancies: A case series 258
Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients 244
miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models 235
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 233
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy 228
HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights 226
Current views on anthracycline cardiotoxicity 222
Prevalence of malnutrition in patients at first medical oncology visit: The PreMiO study 221
18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready? 213
Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study 213
Synchronous papillary carcinoma and hemangiopericytoma with lung metastases 211
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: Implications for personalised treatment 211
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab 205
Patient and Health Care Professional Perspectives: A Case Study of the Lung Cancer Integrated Care Pathway 201
Il protocollo Diagnostico-Terapeutico e Assistenziale per il carcinoma mammario della Regione Emilia-Romagna. I edizione 200
The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: How much does it cost? A retrospecive economic assessment from a single-center experience 199
Ovarian endometrioid adenocarcinoma with a yolk sac tumor component in a postmenopausal woman: Case report and review of the literature 198
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 195
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion 192
Impressive response to dose-dense chemotherapy in a patient with NUT midline carcinoma 186
Estrogen receptor mutation: a new strategy to overcome endocrine resistance 186
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 185
Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: A survey among Italian oncologists 180
Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy 180
Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial) 176
Double-blind, placebo-controlled, multicenter, randomized, phase IIB neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 175
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer 171
Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective 166
Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical Study 165
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 158
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 158
Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study 157
The role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in suspected recovery of breast cancer disease: comparison with Radiological Imaging and impact on patient management 157
Circular RNAs Could Encode Unique Proteins and Affect Cancer Pathways 156
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 153
Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities? 153
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 150
Clinical-diagnostic relevance of breast “incidentaloma” detected during 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography: Correlation with radiological imaging and histopathology 150
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer 148
Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: A double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB) 148
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 148
Primary systemic therapy in operable breast cancer: Clinical data and biological fall-out 148
Tumor infiltrating lymphocytes in triple negative breast cancer and correlations with prognosis 148
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? 146
Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer 146
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 145
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials 144
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study 144
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study 144
Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination 144
Changes of biological features in breast cancer cells determined by primary chemotherapy 144
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: Results of the PerELISA neoadjuvant study 144
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM) 144
Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients 143
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results 141
Risk of second cancer in patients with hairy cell leukemia: long-term follow-up 141
The role of (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) in patients with breast cancer recurrence: a comparison to conventional imaging (CI) techniques and clinical impact on patient management 140
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 140
Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives 139
Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives 138
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278) 138
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke 138
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer 137
The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients 137
Immediate administration of zoledronic acid reduces aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial 136
Predictive value of biologic parameters for primary chemotherapy in operable breast cancer 136
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? 135
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results 135
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting 131
Gene expression profiling in breast cancer: A clinical perspective 129
Erratum: miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models 128
Pattern of distant recurrence according to the molecular subtypes identified by immunohistochemistry in women with early breast cancer 125
The promher study: An observational Italian study on adjuvant therapy for her2-positive, pT1a-b pN0 breast cancer 125
The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma 125
Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer 125
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 121
The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer 121
Gli standard oncologici nel Percorso Diagnostico Terapeutico Assistenziale del paziente con carcinoma del colon: Dati del biennio 2009-2010 presso l'UO di Oncologia Clinica dell'AOU di Ferrara 118
How to fish a good micro-marker out from a worthless lake: The case of cell-free miR-181a-5p and breast cancer 118
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: Extending endocrine sensitivity 118
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 117
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 116
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 115
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 115
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 106
Italian cohort of the nivolumab EAP in squamous NSCLC: Efficacy and safety in patients with CNS metastases 105
Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study 100
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): An exploratory, open-label, phase 2 study 95
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 93
Pulmonary strongyloidiasis mimicking cancer symptoms: A case of hyperinfection in a patient with metastatic lung cancer 92
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study 87
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 86
Totale 18.301
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.051
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.051
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021558 0 0 0 0 0 0 0 0 0 254 167 137
2021/2022844 33 48 53 22 26 109 76 42 57 109 48 221
2022/20231.024 116 59 60 112 134 133 49 124 119 11 71 36
2023/2024582 55 70 27 19 42 88 25 52 12 15 19 158
2024/20252.776 70 76 229 119 345 276 154 150 491 275 310 281
2025/20268.511 636 246 567 866 1.179 454 877 475 2.564 647 0 0
Totale 19.128